Mozaffari Maryam, Naderi Manijeh, Zahednezhad Hosein, Ghadirian Fataneh
Psychiatric Nursing and Management Department, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sci Rep. 2025 Jul 13;15(1):25325. doi: 10.1038/s41598-025-11289-z.
Given the high prevalence of psychological complications during pandemics such as COVID-19, it is imperative to identify effective psychological interventions that can improve the mental health of patients and community members. The effectiveness of mindfulness-based intervention in discharged patients with infectious respiratory diseases, particularly during pandemics, has been examined in a limited number of studies. This study aimed to investigate the effectiveness of an online Mindfulness-Based Stress Reduction (MBSR) training program in alleviating psychological distress, depression, anxiety, and stress among patients who have passed the acute phase of COVID-19 and have been discharged from the hospital. This was a quasi-experimental study included 70 hospitalized patients with COVID-19 (29 [41.4%] men and 41 [58.6%] women) who were discharged from three teaching hospitals in Tehran, Iran, between September 11, 2021, and January 10, 2022 were selected by convenience sampling. Participants were randomly assigned to either the control or intervention group (35 per group). The intervention group received a 4-week online MBSR training program based on Jon Kabat-Zinn's recommendations (2003), while the control group followed the routine hospital discharge plan. Research data were collected using the Lovibond (1995) Depression, Anxiety, and Stress Scale (DASS). The results were compared before and after the intervention. Data analysis was conducted using SPSS version 21, employing descriptive statistics as well as paired and independent sample t-tests. Cohen's d was used to determine effect sizes. The post-test score of stress after the online MBSR training program for 4 weeks significantly decreased in the MBSR group to 12.59 ± 6.77 compared with the control group which had a score of 22.60 ± 10.82(p < 0.001). The total anxiety score significantly decreased, with scores of 8.68 ± 6.52 for the MBSR group versus 18.16 ± 13.37 for the control group (p < 0.001). The depression score in the intervention group (8.68 ± 6.52) was significantly lower compared to the depression score in the control group (18.16 ± 13.37) after the intervention (p < 0.001). This study provides preliminary evidence that online MBSR intervention can serve as an effective measure to reduce depression, stress and anxiety during pandemics such as the COVID-19 crisis. Policymakers and healthcare managers can integrate public mindfulness-based intervention training into crisis management planning to reduce psychological complications and enhance resilience during disasters such as the COVID-19 pandemic.Trial registration. The current study was approved by the Research Ethics Committee of the Faculty of Pharmacy, Nursing and Midwifery of Shahid Beheshti University of Medical Sciences on 10/08/2021 with the registration code IR.SBMU.PHARMACY.REC.1400. 108. In addition, the study protocol was registered with the Iranian Clinical Trial Registration Center on 03/06/2022 under the code IRCT20210715051896N1.
鉴于在新冠疫情等大流行期间心理并发症的高发生率,确定能够改善患者和社区成员心理健康的有效心理干预措施势在必行。基于正念的干预措施对感染性呼吸道疾病出院患者的有效性,特别是在大流行期间,仅在少数研究中得到检验。本研究旨在调查在线基于正念减压(MBSR)培训项目对缓解已度过新冠急性期并已出院患者的心理困扰、抑郁、焦虑和压力的有效性。这是一项准实验研究,纳入了70名新冠住院患者(29名[41.4%]男性和41名[58.6%]女性),这些患者于2021年9月11日至2022年1月10日期间从伊朗德黑兰的三家教学医院出院,采用方便抽样法选取。参与者被随机分为对照组或干预组(每组35人)。干预组接受了为期4周的基于乔恩·卡巴金(2003年)建议的在线MBSR培训项目,而对照组遵循常规出院计划。研究数据使用洛维邦德(1995年)抑郁、焦虑和压力量表(DASS)收集。在干预前后对结果进行比较。使用SPSS 21版进行数据分析,采用描述性统计以及配对和独立样本t检验。使用科恩d值来确定效应大小。与对照组(得分22.60±10.82)相比,MBSR组在接受为期4周的在线MBSR培训项目后的压力后测得分显著降低至12.59±6.77(p<0.001)。总焦虑得分显著降低,MBSR组得分为8.68±6.52,而对照组为18.16±13.37(p<0.001)。干预后,干预组的抑郁得分(8.68±6.52)显著低于对照组(18.16±13.37)(p<0.001)。本研究提供了初步证据,表明在线MBSR干预可作为在新冠疫情等大流行期间减轻抑郁、压力和焦虑的有效措施。政策制定者和医疗管理者可将基于公众正念的干预培训纳入危机管理计划,以减少心理并发症并增强在新冠疫情等灾难期间的恢复力。试验注册。本研究于2021年8月10日获得沙希德·贝赫什提医科大学药学院、护理与助产学研究伦理委员会批准,注册号为IR.SBMU.PHARMACY.REC.1400.108。此外,该研究方案于2022年6月3日在伊朗临床试验注册中心注册,注册号为IRCT20210715051896N1。